Influence of azithromycin and clarithromycin on macrolide susceptibility of viridans streptococci from the oral cavity of healthy volunteers

被引:11
作者
Eisenblaetter, M. [1 ,2 ]
Klaus, C. [1 ,2 ]
Pletz, M. W. R. [3 ]
Orawa, H. [4 ,5 ]
Hahn, H. [1 ,2 ]
Wagner, J. [1 ,2 ]
Lode, H. [6 ]
机构
[1] Free Univ Berlin, Inst Microbiol & Hyg, Charite Univ Med, D-12203 Berlin, Germany
[2] Humboldt Univ, D-12203 Berlin, Germany
[3] Hannover Med Sch, Dept Resp Med, D-30625 Hannover, Germany
[4] Free Univ Berlin, Dept Clin Epidemiol & Biostat, Charite Univ Med, D-10117 Berlin, Germany
[5] Humboldt Univ, D-10117 Berlin, Germany
[6] Helios Klinikum Emil von Behring, Dept Chest & Infect Dis, D-14109 Berlin, Germany
关键词
D O I
10.1007/s10096-008-0547-x
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Oral viridans streptococci are a reservoir of resistance genes for pathogens. Through prolonged exposure, long-acting macrolides (e.g., azithromycin) may induce the resistance of the commensals to macrolides more frequently than macrolides with a shorter half-life (e.g., clarithromycin). In a prospective, randomized, evaluator-blinded trial in healthy volunteers receiving standard courses of either azithromycin (n=20) or clarithromycin (n=20), we compared the susceptibility of oral viridans streptococci to macrolides over a period of 12 weeks. There was a significant temporal increase in the numbers of resistant isolates in both groups (p < 0.0005 at week 1). The proportion of macrolide-resistant isolates over time was significantly higher following azithromycin treatment (p=0.0005), but returned to baseline values until week 12 in both groups. Temporal differential effects of azithromycin and clarithromycin on the induction of resistance were observed and need to be investigated regarding their effect on co-colonizing pathogens.
引用
收藏
页码:1087 / 1092
页数:6
相关论文
共 29 条
[1]   High prevalence of erythromycin-resistant and clindamycin-susceptible (M phenotype) viridans group streptococci from pharyngeal samples:: a reservoir of mef genes in commensal bacteria [J].
Aracil, B ;
Miñambres, M ;
Oteo, J ;
Torres, C ;
Gómez-Garcés, JL ;
Alós, JI .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2001, 48 (04) :592-594
[2]   Antimicrobial resistance in Streptococcus pyogenes isolates in Berlin [J].
Arvand, M ;
Hoeck, M ;
Hahn, H ;
Wagner, J .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2000, 46 (04) :621-623
[3]   Bacterial resistance and antibiotic use in the emergency department [J].
Bennett, J ;
St Geme, W .
PEDIATRIC CLINICS OF NORTH AMERICA, 1999, 46 (06) :1125-+
[4]   Effect of macrolide consumption on erythromycin resistance in Streptococcus pyogenes in Finland in 1997-2001 [J].
Bergman, M ;
Huikko, S ;
Pihlajamäki, M ;
Laippala, P ;
Palva, E ;
Huovinen, P ;
Seppälä, H .
CLINICAL INFECTIOUS DISEASES, 2004, 38 (09) :1251-1256
[5]   Macrolide resistance in Streptococcus pyogenes isolates from throat infections in the region of Aachen, Germany [J].
Brandt, CM ;
Honscha, M ;
Truong, ND ;
Holland, R ;
Hövener, B ;
Bryskier, A ;
Lütticken, R ;
Reinert, RR .
MICROBIAL DRUG RESISTANCE-MECHANISMS EPIDEMIOLOGY AND DISEASE, 2001, 7 (02) :165-170
[6]   Antibacterial resistance patterns in Streptococcus pneumoniae isolated from elderly patients:: PROTEKT years 1-5 (1999-2004) [J].
Canton, Rafael ;
Unal, Serhat ;
Farrell, David J. .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2007, 30 (06) :546-550
[7]  
Cha S, 2001, J Infect Chemother, V7, P81, DOI 10.1007/s101560100013
[8]   The relationship between trends in macrolide use and resistance to macrolides of common respiratory pathogens [J].
Cizman, M ;
Pokorn, M ;
Seme, K ;
Orazem, A ;
Paragi, M .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2001, 47 (04) :475-477
[9]   UNCONSTRAINED BACTERIAL PROMISCUITY - THE TN916-TN1545 FAMILY OF CONJUGATIVE TRANSPOSONS [J].
CLEWELL, DB ;
FLANNAGAN, SE ;
JAWORSKI, DD .
TRENDS IN MICROBIOLOGY, 1995, 3 (06) :229-236
[10]   Antimicrobial susceptibility among communityacquired respiratory tract pathogens in the USA: data from PROTEKT US 2000-01 [J].
Doern, GV ;
Brown, SD .
JOURNAL OF INFECTION, 2004, 48 (01) :56-65